Quick Answer
Xeris Biopharma Holdings, Inc. reported Cash and Equivalents of $111.04 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $111.04M | +55.0% |
| 2024 | $71.62M | +6.2% |
| 2023 | $67.45M | -44.7% |
| 2022 | $121.97M | +81.3% |
| 2021 | $67.27M | +78.9% |
| 2020 | $37.60M | +92.6% |
| 2019 | $19.52M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $91.60M | +54.6% | +54.5% |
| June 30, 2025 | $59.28M | +2.9% | +1.4% |
| March 31, 2025 | $58.44M | -6.8% | -18.4% |
| December 31, 2024 | $71.62M | +6.2% | +20.9% |
| September 30, 2024 | $59.23M | +28.4% | +2.8% |
| June 30, 2024 | $57.60M | +24.8% | -8.1% |
| March 31, 2024 | $62.69M | +23.0% | -7.1% |
| December 31, 2023 | $67.45M | -44.7% | +46.2% |
- Xeris Biopharma Holdings, Inc. showed an increase of +55.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Xeris Biopharma Holdings, Inc.’s cash and equivalents has grown by 468.9% (from $19.52 million to $111.04 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: